Our objective is to summarize the key components of a health economic evaluation of
antithrombotic treatments for stroke prevention in patients with atrial fibrillation (AF). The key …

Atrial fibrillation (AF) is an independent predictor of stroke and heart failure. Stroke, in
particular, is more severe and costly in AF than in non-AF patients. Direct costs to Medicare …

Objectives To summarize healthcare costs incurred from patients with atrial fibrillation (AF)
who developed ischemic stroke and to explore the factors associated with increased cost …

Background Use of oral anticoagulation therapy in patients with atrial fibrillation (AF)
involves a trade-off between a reduced risk of ischemic stroke and an increased risk of …

Objectives: To estimate the 1-year stroke-related cost to manage ischemic stroke (IS) and
hemorrhagic stroke (HS) events in a population with atrial fibrillation (AF). Study Design …

Background and Purpose—A number of clinical trials have shown the value of
anticoagulating patients with nonrheumatic atrial fibrillation to prevent ischemic stroke. The …

Background Stroke represents a major complication of atrial fibrillation (AF). The current
anticoagulation options for stroke prevention increase hemorrhage risk. The objective of the …

Stroke associated with atrial fibrillation may occur in up to one third of people who
experience an ischemic event, and results in greater stroke severity and poorer health …

Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …

Background Previous investigations into the cost effectiveness of direct oral anticoagulants
only considered individual stroke risk but not bleed risk even though bleeding is an …